Les Meilleurs doctors pour le traitement de métaplasie gastrique en Israël - TOP-7 des médecins

Le Dr Pelles Sharon est une oncologue hautement respectée, spécialisée dans la chirurgie du cancer de l'estomac au centre médical Sourasky (Ichilov).

• Mener des recherches cliniques novatrices sur l'attitude des patients oncologiques vis-à-vis des essais cliniques
• Réaliser des procédures avancées telles que l'opération HIPEC et la chirurgie de Whipple
• Être qualifiée dans les traitements oncologiques chirurgicaux et non chirurgicaux

Spécialisé dans la chirurgie abdominale ouverte et mini-invasive, y compris la procédure complexe de Whipple. Il dirige le département de chirurgie colorectale du centre médical Sourasky (Ichilov).

• Plus de 20 ans d'expérience en chirurgie
• Expert en techniques mini-invasives avancées
• Chef de service, à la tête d'une équipe chirurgicale spécialisée

En tant que chef du centre d'oncologie gastro-intestinale, le Dr Hubert dirige une unité spécialisée dans les cancers digestifs complexes.

• 33 ans d'expérience clinique en oncologie et radiothérapie
• Double certification de spécialiste en oncologie et en radiothérapie
• Médecin senior à l'hôpital universitaire Hadassah
• Membre actif du comité israélien pour le cancer gastro-intestinal
• Formation comprenant à la fois un doctorat en médecine et un diplôme en psychologie

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.